Semaglutide

Semaglutide (Ozempic, Wegovy, Rybelsus) is a potent GLP-1 (glucagon-like peptide-1) receptor agonist used for managing type 2 diabetes and chronic weight management. It mimics the effects of the natural incretin hormone GLP-1, which is released after eating. Semaglutide works by increasing insulin release from the pancreas in response to glucose, decreasing glucagon secretion (which lowers liver glucose production), and slowing gastric emptying, which helps control post-meal blood sugar spikes and promotes satiety. In the brain, it acts on areas regulating appetite, leading to reduced hunger and calorie intake. Clinical trials have shown significant improvements in blood sugar control and substantial weight loss in individuals with or without diabetes. It also offers cardiovascular benefits in people with type 2 diabetes.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a prolonged half-life of approximately 7 days. This educational protocol presents a gradual weekly titration from 0.25 mg up to a maintenance dose of 2.4 mg over 16+ weeks. Weekly dose range: 250–2400 mcg (0.25–2.4 mg) once weekly.